RODMAN&RENSHAW upgraded shares of TuHURA Biosciences (NASDAQ:HURA – Free Report) to a strong-buy rating in a report released on Thursday morning,Zacks.com reports.
A number of other research analysts have also recently commented on the company. Rodman & Renshaw started coverage on TuHURA Biosciences in a research report on Thursday. They set a “buy” rating and a $11.00 price target on the stock. Maxim Group started coverage on shares of TuHURA Biosciences in a report on Tuesday, November 5th. They issued a “buy” rating and a $15.00 price target on the stock.
View Our Latest Analysis on TuHURA Biosciences
TuHURA Biosciences Price Performance
TuHURA Biosciences Company Profile
TuHURA Biosciences, Inc (NASDAQ: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA’s lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors.
Further Reading
- Five stocks we like better than TuHURA Biosciences
- ETF Screener: Uses and Step-by-Step Guide
- Ad Sales to Top $1 Trillion: 3 Stocks to Take Advantage
- Business Services Stocks Investing
- Micron Stock Under $100: Seize the AI-Driven Upside
- 3 Grocery Stocks That Are Proving They Are Still Essential
- AI’s Next Big Winners: 3 Small-Cap Stocks to Watch in 2025
Receive News & Ratings for TuHURA Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TuHURA Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
